Johnson & Johnson

Johnson & Johnson (JNJ) (Q4FY23) – Evaluating strategic outlook amidst headwinds

Highlights of the report

Johnson & Johnson faces competitive pressures and the loss of exclusivity for several key products, which could impact future revenue growth.

Johnson & Johnson (JNJ) Equity Report Q4FY23

CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.


CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).


Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide.

JNJ’s revenue has increased by 7% to $21.39bn in Q4FY23 from $19.93bn in Q4FY22, Gross profit increased to $14.68bn in Q4FY23 from $13.85bn in Q4FY22 and the company’s gross margin is stable at 69% in Q4FY23 and Q4FY22.

In the past 1 year, JNJ generated returns of 1.60% where the stock price increased to $155.76 as on Mar 20, 2024 from $153.30 in Mar 27, 2023. Over the past 3 years JNJ generated negative returns of (2.95%) where the stock decreased to $155.76 as on Mar 20, 2024 from $160.50 in Mar 22, 2021.



– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance


Stock Price Performance

Crispidea Coverage

Report details

Johnson & Johnson (JNJ) (Q4FY23) – Evaluating strategic outlook amidst headwinds



Company Reports

Sector Reports